Advisory Board

Wolf H. Fridman, MD, PhD
Dr. Wolf H. Fridman is the Director of the Cordeliers Research Centre and Head of the Department of Immunology, Hôpital Européen Geaorges Pompidou in Paris. Dr. Fridman is an expert in cellular and tumor immunology and the author of more than 300 international publications in these fields. His research interests lay in the structure and function of the cellular receptors for IgG antibodies, the role of cytokines in the control of tumor development and the design of novel strategies for therapeutic vaccination of cancer. Dr. Fridman, M.D., Ph.D., was chairman of the department of clinical biology and head of the laboratory of clinical immunology at the Institut Curie in Paris. He was also commissioner of the French government’s Agence du Medicament, the equivalent of the U.S. Food and Drug Administration. In addition, Fridman has served as chief, cellular immunology group, Institut de Recherches Scientifiques sur le Cancer in Villejuif, France. He received his M.D. from the University of Paris and his Ph.D. from the University Pierre et Marie Curie.
 

Leo I. Gordon, MD
Leo I. Gordon, MD is Professor of Medicine and Director, Lymphoma Program, Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine. He obtained his medical degree from the University of Cincinnati. He completed his internship and residency in internal medicine at the University of Chicago Hospitals and Clinics. He then went on to complete his fellowship in hematology at the University of Minnesota, and Hematology/ Oncology at the University of Chicago. Dr. Gordon’s clinical research interests focus on hematologic malignancies, especially Hodgkin’s and non-Hodgkin’s lymphomas (NHL) and bone marrow transplantation (BMT). He is co-chair of the Eastern Cooperative Oncology Group (ECOG) Lymphoma Committee. He has conducted clinical trials in NHL incorporating prognostic factor analysis in data assessment. He is leading trials of radiolabeled monoclonal antibodies in low-grade lymphomas and combined modality approaches to mantle cell lymphomas and Hodgkin’s disease. In the laboratory, Dr. Gordon is investigating the mechanisms of apoptosis induced by free radicals in lymphoma and myeloma cell lines, developing the concept of redox-regulation as a means of cellular cytotoxicity in cancer. Dr. Gordon is chair of the Oncological Sciences Study Section at the National Cancer Institute. He also belongs to numerous societies such as the American Federation of Clinical Research, the American Society of Clinical Oncology, the American Society of Hematology and the American Association of Cancer Research. Dr. Gordon has authored over 100 manuscripts for numerous professional publications such as Blood, the New England Journal of Medicine, Cancer Research, Clinical Cancer Research, the Journal of Clinical Investigation and the Journal of Clinical Oncology.

Arnon Nagler, MD, M.Sc.
Dr. Arnon Nagler is a Professor of Medicine at the Tel Aviv University, Sackler School of Medicine and the Director of the Division of Hematology, Bone Marrow Transplantation and Cord Blood Bank at Chaim Sheba Medical Center, Tel Hashomer, Israel.  Dr. Nagler obtained his medical degree from the Hebrew University, Jerusalem and his M.Sc. in cell biology from the Tel Aviv University, Tel Aviv. Prof. Nagler completed residency at the Hadassah University Hospital and was further trained in Internal Medicine and Hematology at the Rambam Center in Haifa, Israel. Before joining Chaim Sheba Medical Center, Dr. Nagler was Senior Physician in the Hadassah Medical Center Department of Bone Marrow Transplantation and Head of the Israel National Human Umbilical Cord Blood Bank at the Hadassah Medical Center. Before that Dr. Nagler was visiting Scientist at the DNAX Research Institute in California and Research Associate at the Hematology Department of Stanford Medical Center. Dr. Nagler’s major research interests are: cord blood biology, adoptive cell mediated immunotherapy, NK and CTL Activity, transplantation in hemato-oncologic malignancies and the role of Collagen Type I in fibrotic disorders. Dr. Nagler is a member of; the American Society of Hematology, The International Bone Marrow Transplant Registry, the International Cord Blood, the American Association of Blood Banking, the ISCT and other organizations. Dr. Nagler is the author of numerous scientific articles and chapters in medical books.

Edie A. Weller, PhD
Dr. Weller is Senior Research Scientist at the Department of Biostatistics, Harvard School of Public Health and Research Scientist at the Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute. Dr. Weller’s major activities include the design, analysis, and conduct of phase I, II, and III clinical trials as well as laboratory and animal studies. She collaborates with investigators at the Dana-Farber/Harvard Cancer Center (DF/HCC) in the area of multiple myeloma (MM) and with the Eastern Oncology Cooperative Group (ECOG) in the area of lymphoma. In addition, she is the lead statistician on the Lunenburg Lymphoma Biomarker Consortium, an international effort to validate the prognostic relevance of important biomarkers in large clinical trials of non-Hodgkin’s lymphoma. Dr. Weller received her PhD in biostatistics from the Medical College of Virginia at Virginia Commonwealth University in 1992, followed by postdoctoral training at Harvard School of Public Health. In 1995, she joined DFCI as a research scientist and was promoted to senior research scientist in 2001.